FAQ: Branded Legacy, Inc. (OTC: BLEG) Acquisition of Bio Legacy Evaluative Group

What is the significance of Branded Legacy’s acquisition of Bio Legacy Evaluative Group?

The acquisition allows Branded Legacy to enter the biotech and medical devices sector, addressing critical global health issues such as the addiction epidemic and vaccine distribution inefficiencies with innovative solutions like a patented intranasal naloxone device.

How was the acquisition transaction structured?

The deal was an all-stock transaction valued at $1.5 million in Preferred D shares, including performance-based conversion milestones, a two-year lock-up, and a $1 million R&D commitment post-uplisting to OTCQB.

What products or technologies does Bio Legacy Evaluative Group bring to Branded Legacy?

Bio Legacy brings a patented all-in-one intranasal naloxone device targeting a rapidly growing market and technology for nasal delivery of vaccines and cold-chain therapies.

When was the acquisition completed?

The acquisition was closed on July 31, 2025.

What are the projected market growth figures for the intranasal naloxone device?

The market for the intranasal naloxone device is projected to grow from $371 million in 2022 to over $1.16 billion by 2032.

Who is leading Bio Legacy Evaluative Group under Branded Legacy?

Amin Janmohamed is the CEO of Bio Legacy Evaluative Group under Branded Legacy.

Where can I find more information about Branded Legacy and this acquisition?

For more information, visit Branded Legacy’s website at https://BrandedLegacy.com or view the full press release at https://ibn.fm/U7eSy.

What is the focus of Branded Legacy Inc.?

Branded Legacy specializes in the development and commercialization of biotech and wellness products, focusing on strategic growth, innovation, and quality to enhance lives and create sustainable value for its shareholders.

What does the acquisition include beyond the initial transaction?

Beyond the initial transaction, the acquisition includes performance-based conversion milestones, a two-year lock-up period, and a $1 million R&D commitment after uplisting to OTCQB.